GlassScriptPhysician profile
Sylvia Irizarry
NPI 1144284332
$846.60
in general payments reported to CMS, 2019-2025
14 companies · $217 in 2025
The $217 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $17.34 · 2021: $48.27 · 2022: $94.26 · 2023: $172 · 2024: $98.80 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.71 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $160.01 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Sobi, INC | $122.73 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $104.63 | 2019-2023 | Brilinta |
| Janssen Pharmaceuticals, INC | $74.83 | 2022-2025 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $73.75 | 2023-2025 | |
| Inspire Medical Systems, INC. | $53.79 | 2023 | Inspire |
| Cranial Technologies, INC | $49.55 | 2020-2022 | |
| Pfizer INC. | $48.28 | 2023-2025 | |
| Amgen INC. | $46.99 | 2022-2024 | Repatha |
| Exact Sciences Corporation | $37.52 | 2025 | The Cologuard Plus Collection Kit |
| Phadia US INC. | $27.40 | 2021-2022 | |
| Amarin Pharma, INC. | $17.30 | 2021 | |
| Sumitomo Pharma America, INC. | $15.24 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $14.58 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Irizarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.